Navigation Links
PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
Date:3/20/2008


Strategic Acquisition Reinforces PharmAthene's Status

as a Premier Biodefense Company;

Creates Expanded Biodefense Pipeline

ANNAPOLIS, Md., and TEES VALLEY, England, March 20 /PRNewswire-FirstCall/ -- PharmAthene, Inc., a biodefense company specializing in the development and commercialization of medical countermeasures against biological and chemical threats, and Avecia Biologics Limited, a contract manufacturer of biopharmaceuticals, announced today that the companies have entered into a definitive sale and purchase agreement under which PharmAthene will acquire all of the assets and intellectual property related to Avecia's biodefense vaccines business. This includes a second generation recombinant Protective Antigen (rPA) anthrax vaccine, a recombinant dual antigen plague vaccine, and a third generation rPA anthrax vaccine program. As part of this agreement, PharmAthene and Avecia Biologics have entered into a long-term manufacturing contract for the supply of these vaccine drug substances to PharmAthene.

David P. Wright, President and Chief Executive Officer of PharmAthene, commented, "Our acquisition of Avecia's biodefense vaccine assets significantly advances PharmAthene's strategy of building a leading biodefense company with a comprehensive portfolio of medical countermeasures that specifically meet the requirements for procurement established by the United States Government. Importantly, the rPA anthrax vaccine presents a promising near-term procurement opportunity for PharmAthene based upon a recently issued government solicitation outlining requirements to procure 25 million doses of an rPA vaccine."

Eric I. Richman, PharmAthene's Senior Vice President of Business Development & Strategic Planning commented, "Our two companies have a proven track record in successfully collaborating with the U.S. and U.K. Governments in the development of biodefense medical counter
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
2. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
3. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
4. PharmAthene to Present at the BIO CEO & Investor Conference 2008
5. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
6. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
7. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
10. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
11. Corgenix Signs Technology Licensing Agreement With Japanese Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project managed ... legal requirements around using controlled substances in pharmaceutical research, ... their international operations expand and become increasingly complex, large ... a result of the first phase of the CSCS ...
(Date:1/22/2015)... , Nueva Jersey , 22 de enero ... for Biomedical Research abre hoy su llamada a nominaciones ... cuya investigación científica ha hecho, o tiene el potencial ... salud humana. Las nominaciones se aceptarán hasta el 15 ...
(Date:1/22/2015)... Jan. 22, 2015   GenoSpace , a precision medicine software ... enable the broad use of genomic, imaging and other biomedical ... of Michelle Munson , CEO of Aspera, an IBM ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We are ...
(Date:12/24/2014)... SPRING, Md. , Dec. 24, 2014  United Therapeutics ... Medtronic, Inc. (NYSE: MDT ) has submitted ... Drug Administration (FDA) for the use of Medtronic,s SynchroMed ... newly developed catheter) for use with United Therapeutics, Remodulin ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... , LAGUNA HILLS, Calif., July 22 ... therapies to treat cardiac abnormalities, announced today that it has changed ... , CardioPolymers, Inc. Chief Executive Officer Raymond ... reflects our focus on employing natural biocompatible polymer implants to treat ...
... , , CHICAGO, July ... Chemistry (AACC) annual meeting today indicates that monitoring cardiac transplant ... analyzer may help clinicians to monitor cyclosporine-induced toxicity and adjust ... , , In ...
... , ... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) and ... entered into a licensing agreement for antibody therapeutic rights under ... Under the terms of the agreement, Affitech will license exclusive ...
Cached Biology Technology:Symphony Medical Changes Name to CardioPolymers, Inc. 2Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients 2Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech 2Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech 3Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech 4Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech 5
(Date:12/22/2014)... , Dec. 22, 2014  The 2014 Holiday Season may ... Acuity Market Intelligence reports that the long anticipated floodgates ... that intensifying demand for smart phones, tablets, and wearable ... market of 2.5 billion users with nearly 4.8 billion ...
(Date:12/17/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally ... for the first time a fingerprint sensor in its ...
(Date:12/17/2014)... Dec. 16, 2014  Automation is fundamentally transforming the travel ... international borders. Over the past decade, ePassports, biometric readers, ... self process through border control via eGates and Automated ... airports, seaports, and land borders across the globe. ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... in a mouse model a new, locally applied treatment for ... size of the tumor, but does so without causing the ... to be suitable for certain forms of breast, lung, prostate ... even in countries with limited resources. , A report ...
... 5-year study examining why dead zones have returned to Lake ... detect the cause and stop the spread before the fishery ... serious problem," said University of Michigan's Donald Scavia, professor in ... of the project. "In the 1960s and 1970s the Lake ...
... in the brain induced by early experience, research shows ... team found that when baby rhesus monkeys endured high rates ... of life, their brains often produced less serotonin, a chemical ... are associated with anxiety and depression and impulsive aggression in ...
Cached Biology News:St. Jude announces breakthrough in eye cancer treatment 2St. Jude announces breakthrough in eye cancer treatment 3St. Jude announces breakthrough in eye cancer treatment 4Researchers to study why dead zone returned to Lake Erie 2Low levels of neurotransmitter serotonin may perpetuate child abuse across generations 2Low levels of neurotransmitter serotonin may perpetuate child abuse across generations 3
tracking dye in electrophoresis; free acid, C 19 H 10 BrO 5 S; MW: 669.96...
... 22K enables researchers to simultaneously characterize ... biological functions, growth processes, and biotic ... contains sequences representing estimated coverage of ... focuses on well annotated genes selected ...
... technology, SilenceMag is the most efficient ... and easy to use, SilenceMag is ... designed for siRNA delivery, SilenceMag allows ... doses of siRNA.,SilenceMag formulation gives reliable ...
... Cytological Labeling Kit provides a unique signal ... cellular targets, including cell-surface receptors and subcellular ... contains the patented ELF 97 phosphatase substrate, ... at the site of enzymatic activity ...
Biology Products: